The article on the treatment of motor neuron syndromes by Tan et al1 contains inaccurate statements regarding methods used to measure and report anti—GM1 ganglioside antibodies in our laboratory. The results reported by our laboratory correspond closely to the reciprocal of true dilutions. This is stated in the "Methods" section of each of our articles.2,3 We have participated in two international validation studies.4,5 These studies show that our results correlate with those from other laboratories that express their results as titers. It is highly unlikely that serum samples with a titer measured at 1:200 in their laboratory would be reported at 64000 by ours. Such high titers are rare in patients with lower motor neuron syndromes.2 The citation in the "Methods" section of the article by Tan et al of a serum with a titer of 1:64000 was not data from our laboratory as we
Pestronk A. Immunosuppressive Treatment of Motor Neuron Syndromes. Arch Neurol. 1995;52(3):230. doi:10.1001/archneur.1995.00540270016004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: